Clinical Trial Update: Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the effectiveness and safety of three fixed doses (25 mg eq., 100 mg eq., and 150 mg eq.) of paliperidone palmitate in patients with sc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Paliperidone palmitate (Paliperidone palmitate)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2009-10-05